Active, not recruitingPhase 3NCT05222906
Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3
Studying Gaucher disease type 3
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sanofi
- Principal Investigator
- Clinical Sciences & OperationsSanofi
- Intervention
- Venglustat(drug)
- Enrollment
- 43 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2022 – 2025
Study locations (20)
- Yale University School of Medicine - Investigational Site Number: 8400003, New Haven, Connecticut, United States
- University of Iowa - Investigational Site Number: 8400002, Iowa City, Iowa, United States
- Texas Oncology - Medical City Dallas Site Number : 8400008, Dallas, Texas, United States
- Lysosomal & Rare Disorders Research & Treatment Center, Inc - Investigational Site Number: 8400001, Fairfax, Virginia, United States
- Hospital de Ninos - Investigational Site Number: 320001, Buenos Aires, Argentina
- Children's Hospital Research Institute of Manitoba - Investigational Site Number: 1240001, Winnipeg, Manitoba, Canada
- National Taiwan University Hospital-Investigational Site Number: 1580001, Taipei, Taiwan, China
- Peking Union Medical College Hospital - Investigational Site Number: 1560001, Beijing, China
- The First Affiliated Hospital - Investigational Site Number: 1560002, Guangzhou, China
- Xinhua Hospital - Investigational Site Number: 1560004, Shanghai, China
- 47-87, boulevard de l'hôpital - Investigational Site Number: 2500003, Paris, France
- Hopital Necker - Investigational Site Number: 2500001, Paris, France
- SphinCS GmbH - Investigational Site Number: 2760001, Hochheim am Main, Germany
- Debreceni Egyetem, Klinikai Központ, Reumatológiai Klinika - Investigational Site Number: 3480001, Debrecen, Hungary
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Investigational Site Number : 3800003, Milan, Lombardy, Italy
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05222906 on ClinicalTrials.govOther trials for Gaucher disease type 3
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNANCT07285369High-Dose Ambroxol in Pediatric Type III Gaucher Disease (GD3)Agyany Pharma LTD
- ENROLLING BY INVITATIONNANCT06627543Effect of Enzyme Replacement Therapy on Cardiac Function in Children With Gaucher Disease Type 3Noha Osman
- RECRUITINGNANCT06162338A Study of the Safety and Preliminary Efficacy of LY-M001 Injection in the Treatment of Adult Patients with Gaucher Disease Type IHe Huang
- RECRUITINGNANCT05586243MAGNETIC RESONANCE SPECTROSCOPY BIOMARKERS IN TYPE 3 GAUCHER DISEASE (GD3)University of Minnesota
- RECRUITINGNANCT03240653Gaucherite - A Study to Stratify Gaucher DiseaseCambridge University Hospitals NHS Foundation Trust